On November 13th, 2017 The United States Department Of Transportation, DOT, published its final rule regarding DOT drug and alcohol policy.
The DOT compliant drug screening will expand its current 5-panel urine test, to include expanded testing on Opiates, including Hydromorphone, Oxymorphone, and Oxycodone.
Effective January 1st, 2018 a DOT urine drug analysis will test for
The opiates category of a 5-panel drug screen tests for the illicit drug heroin, and the licit drugs codeine and morphine.
Please be advised, due to the addition of the number of drugs being tested, a small price increase on DOT drug tests will take effect.
Our labs, Medical Review Officers, and CEO will review this new panel and provide additional information as it becomes available.
Accredited Drug Testing will add an amendment in its policy regarding these changes, effective January 1st, 2018.
Things to remember
1. Blind specimen testing is no longer required.
Blind specimen testing is a specimen submitted to a laboratory for quality control testing purposes, with a fictitious identifier, so that the laboratory cannot distinguish it from an employee specimen.
You should not order new CCF forms– the current CCF forms are valid until June 30th, 2018. If you have not yet done so, now would be a good time to look into eCCF forms ( Electronic CCF). Doing this will save you time and save you the hassle of shipping and storing paperwork.
For any other questions regarding DOT Compliance – please email email@example.com, or reach us directly at (800)221-4291.